The Cervical Cancer Screening Industry shall experience a CAGR of nearly 4.57% from 2022 to 2028. Cervical cancer begins in the cells of the cervix, the bottom section of the uterus attaching to the vagina. The illness advances gradually, with dysplasia alterations preceding cancer growth. Detecting precancerous cell alterations via screening is vital to prevent cervical cancer. Early-stage cervical cancer is more controllable, making screening crucial. The increased acceptance of diagnostic tests in healthcare organizations generates chances for the Cervical Cancer Diagnostic Test Market. Key companies globally are releasing sophisticated technology-based goods, favourably benefiting the sector.
For instance, according to the American Society of Clinical Oncology, over 604,127 women were diagnosed with cervical cancer worldwide in 2020, with around 341,831 deaths. Increasing cancer detection knowledge fuels market development and the World Health Organization has set a target to eradicate cervical cancer as a public health concern worldwide by 2120. To accomplish this, numerous objectives should be fulfilled by 2030, including HPV vaccination, high-performance screening, treatment for pre-cancer, and care for invasive cancer. A regional plan has been designed for the WHO Eastern Mediterranean Region to match with its distinctive situations. The cervical cancer screening industry has developed owing to greater awareness, education, and enhanced screening technology. Demand for screening services and products have grown, leading to additional research and development. Government efforts and awareness campaigns also had a part in industry expansion.
|Historical Period||2018 – 2022|
|Forecast Period||2023 – 2028|
|Tests Covered||Pap Smear Test, HPV DNA Test, and VIA Test|
|Countries Covered||United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway, Netherlands, United States, Canada, Japan, Korea, Singapore, Malaysia, India, China, Indonesia, Thailand and Rest of world|
|Companies Covered||Abbott Laboratories, Becton, Siemens AG, Quest Diagnostics, Roche, Hologic Corporation and Cardinal Health|
|Customization Scope||20% Free Customization|
|Post-Sale Analyst Support||1 Year (52 Weeks)|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request)|
The HPV DNA test screening market is rising due to greater awareness of the association between HPV and cervical cancer, emphasizing early identification and prevention.
The HPV DNA test screening industry has developed dramatically owing to greater knowledge of HPV’s relation to cervical cancer. This has pushed the focus on early identification and prevention. HPV DNA testing successfully identifies high-risk strains, resulting in early detection and prompt treatments. Advancements in testing technology have enhanced accuracy, uptake, and convenience via FDA-approved self-collection kits. Government actions and healthcare organizations encouraging regular HPV DNA screening have spurred market expansion. Public health efforts have improved awareness among women about the significance of regular HPV DNA testing. As research and technology continue to advance, the market is likely to increase further, adding considerably to lowering the prevalence of cervical cancer worldwide.
Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=global-cervical-cancer-screening-market-and-patients-by-test-type-pap-smear-hpv-dna-via-forecast-1009-p.php
Type – The Report covers cervical cancer screening market, by type in 3 viewpoints
- Pap Smear Tests Market
- HPV DNA Tests Market
- VIA Tests Market
Government policies contribute to the increasing demand for cervical cancer screening in the United States.
The US cervical cancer screening industry is crucial for women’s healthcare, detecting HPV-linked cervical cancer early for better treatment. Growing due to heightened awareness and education, common methods include Pap smear and HPV DNA testing with improved technologies. HPV vaccination programs further prevent cases. Government and healthcare initiatives promote regular screenings, reducing cervical cancer rates and supporting public health efforts. The ACOG, ASCCP, and SGO suggest commencing cervical cancer screening at age 21. Healthcare practitioners should promote the HPV vaccination for cervical cancer prevention. Awareness from established companies will raise demand for screening, offering chances for low-cost health checks and market development.
Country – By country, the cervical cancer screening market, breakup in 20 viewpoints
- United Kingdom
- United States
- Rest of World
Abbott Laboratories, Becton, Siemens AG, Quest Diagnostics, Roche, Hologic Corporation, and Cardinal Health are among the largest companies in the cervical cancer screening industry.
Companies have been covered from 3 viewpoints
- Recent Development
- Abbott Laboratories
- Siemens AG
- Quest Diagnostics
- Cardinal Health
- Hologic Corporation
About the Company:
Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000 syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Email: [email protected]